Trade Names:Berinert- Injection, lyophilized powder for solution 500 units
Trade Names:Cinryze- Injection, lyophilized powder for solution 500 units
Regulates the activation of the complement and intrinsic coagulation (contact system) pathway and also regulates the fibrinolytic system.
C max is 0.68 units/mL and T max is 3.9 h ( Cinryze ).
V ss is 11.1 to 56.1 mL/kg ( Berinert ).
Half-life is 56 h ( Cinryze ); 7.4 to 24.4 h ( Berinert ).
Pharmacokinetic studies have not been conducted in patients with renal impairment.Hepatic Function Impairment
Pharmacokinetic studies have not been conducted in patients with hepatic impairment.Children
Compared with adults, the half-life was shorter and Cl was faster ( Berinert ).
Treatment of acute abdominal or facial attacks of hereditary angioedema in adult and adolescent patients.Cinryze
Routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema.
Life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to these products.
20 units/kg body weight.Cinryze
1,000 units every 3 or 4 days.
Store at 36° to 77°F. Do not freeze. Protect from light. Use reconstituted solution promptly or within 8 h if stored up to 77°F. Do not refrigerate or freeze the reconstituted solution.Cinryze
Store at 36° to 77°F. Do not freeze. Protect from light. Use reconstituted solution within 3 h of reconstitution.
None well documented.
None well documented.
Abdominal pain, nausea (7%); diarrhea, dysgeusia, vomiting (5%).
Pain on injection, redness at injection site (postmarketing).
Muscle spasms (6%); back pain, limb injury, pain in extremities.
Bronchitis, sinusitis, upper respiratory tract infections, viral upper respiratory tract infection.
Pain (6%); nasopharyngitis (5%); chills, fever, hypersensitivity/anaphylactic reactions, shock (postmarketing).
Monitor all patients for thrombotic and hypersensitivity reactions.
Category C .
Safety and efficacy not established in children younger than 13 yr of age.
Severe hypersensitivity reactions may occur.
Because C1 inhibitor is prepared from human blood, there is a risk of transmitting infectious agents (eg, viruses), including Creutzfeldt-Jakob disease.
Have been reported when used off-label at high doses.
Overdosage has not been reported.
Copyright © 2009 Wolters Kluwer Health.